GLP-1 receptor agonist
Liraglutide
An established GLP-1 medicine whose evidence belongs to specific products, indications, populations, and current labels.
Also known as Victoza · Saxenda · GLP-1 analogue
01 · Evidence profile
One molecule, four evidence questions
Large randomized programs support defined glycemic, cardiovascular, and weight-management outcomes.
Approved labels characterize product-specific exposure, pharmacodynamics, and interactions.
Current labels describe contraindications, warnings, adverse reactions, and monitoring.
High for authentic approved products; evidence does not transfer automatically to unapproved versions.
02 · Identity
What it is
Liraglutide is a modified GLP-1 analogue used in prescription medicines. The ingredient name alone does not specify the product, indication, formulation, or labeled population.
03 · Product identity
The molecule is not the finished product.
Liraglutide is an active ingredient. Victoza and Saxenda are distinct approved products with different labeled indications and product-specific prescribing information.
Victoza
November 2024- Formulation
- Injection
- Route
- Subcutaneous
- Indication scope
- Type 2 diabetes uses and labeled populations defined in the current product prescribing information.
Saxenda
February 2026- Formulation
- Injection
- Route
- Subcutaneous
- Indication scope
- Chronic weight management in the adult and pediatric populations defined in the current label.
- Victoza
- Saxenda
- Type 2 diabetes for labeled populations
- Chronic weight management for labeled populations
04 · Evidence snapshot
What the evidence can and cannot say
Randomized trials and FDA-reviewed labels support specific outcomes. LEADER studied cardiovascular outcomes in adults with type 2 diabetes at high cardiovascular risk. Saxenda has a separate chronic weight-management label.
Those results do not establish identical benefit for every person, an anti-aging effect, or equivalence between approved products and compounded, counterfeit, or research-labeled material.
05 · Claim check
Three claims under the lens
“Liraglutide has established human outcome evidence.”
Yes, for defined products, populations, indications, comparators, endpoints, and durations studied in major trials and reviewed labels.
- Evidence basis
- Randomized human outcomes
- Scope
- Approved liraglutide products used in the populations and indications studied.
“Every product sold as liraglutide is clinically equivalent.”
Approved-product evidence includes product quality and labeling that cannot be assumed for every compounded or unapproved item.
- Evidence basis
- Regulatory or product record
- Scope
- Product identity, formulation, quality, and labeling all matter.
“Cardiovascular trial results prove a universal longevity benefit.”
LEADER tested a defined cardiovascular composite in a high-risk type 2 diabetes population, not lifespan extension in the general population.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults with type 2 diabetes and high cardiovascular risk in LEADER.
06 · Safety boundary
Before this becomes personal
The current label contains important contraindications, warnings, and precautions. This guide does not determine eligibility or provide dose, titration, or product-switching instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed 2026-07-23. This status is not personal clearance to compete.07 · Sources
Check the primary record
08 · Provenance
Review history
Initial brief based on the current Saxenda label, LEADER, and FDA product records.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.